Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
836.6 EUR | -4.28% |
|
+2.14% | +66.00% |
06:24pm | Global markets live: Adidas, TSMC, Vale, HSBC, J&J... | ![]() |
04:18pm | Stocks to watch as Biden, Trump vie for presidency | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- With an expected P/E ratio at 70.42 and 50.28 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+66.00% | 848B | - | ||
+31.64% | 627B | B | ||
+0.03% | 363B | C+ | ||
+15.43% | 318B | B- | ||
+12.67% | 299B | C+ | ||
+15.51% | 243B | B+ | ||
+16.72% | 225B | B- | ||
+16.35% | 179B | C+ | ||
+4.13% | 167B | C+ | ||
+2.52% | 125B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LLY Stock
- 4LLY Stock
- Ratings Eli Lilly and Company